other panelists were receiving research money, performed speeches promoting the medication, or owned stocks in the companies that manufactured the pharmaceuticals they recommended [5] .
In an excellent and thorough review of physician-industry conflicts of interests, Dr. Lichter from the University of Michigan discusses in detail how a sense of entitlement, recognition, sense of belonging, and money motivate physicians to deny the influence of the pharmaceutical industry over their practice. The compensated physician often feels gratitude for the monetary generosity of the pharmaceutical company and praises them publicly, ultimately providing bargain advertising. In conclusion, the author suggests simple disclosure may not be enough and that physicians must ask themselves, "Could this be a bribe?" As physicians we must first do what is best for our patients and the public. Industry does not share this bottom line; it has an obligation of profit and not a Hippocratic Oath [6] . The cold hard facts of the influence of the pharmaceutical industry have been reported in a multitude of prominent journals [7] [8] [9] [10] [11] [12] [13] .
The nature of our specialty does not entirely shield us from conflicts of interest. In caring for patients who are often therapeutic orphans, some of our brilliant pioneers have relied on pharmaceutical companies to fund research, fellows, and even salaries as a means to achieve a noble end. I have not attended a toxicological conference organized by the American Academy of Clinical Toxicology, American Association of Poison Control Centers, or American College of Medical Toxicology that was not partially funded by the pharmaceutical industry. These subsidized meetings serve an essential role for our continuing medical education and that of our specialists in poison information, educators, and toxicology fellows, as well as advancing the specialty.
As toxicologists, individually and as a group, we need to reevaluate the influence of the pharmaceutical industry in the conferences we attend, in the journals that we read, in the research we perform, in the direction of our teaching, and in our daily practice of medicine. Instead of treating the nausea from our free lunch with the newest antiemetic, the antidote for this gastrointestinal toxin is a change in diet. We are obligated to present information with equanimity, integrity, and accountability. Simple disclosure does not exempt us from the systematic bias of pharmaceutical industry-sponsored activi- 
